Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial
These findings support setmelanotide as a novel effective treatment of hypothalamic obesity.
These findings support setmelanotide as a novel effective treatment of hypothalamic obesity.
This study presents both qualitative and quantitative evidence of the presence of MPs, and their mass concentrations, polymer types, and physical properties in thrombotic diseases…
In honor of National Asian American and Pacific Islander Heritage Month, Endocrine News reached out to several of our U.S.-based Asian members to get their…
Find out how diabetes can affect women differently than men
Multiple myeloma remains an incurable disease, despite the development of numerous drug classes and combinations that have contributed to improved overall survival. Immunotherapies directed against…
This week only, take advantage of our special members-only period for ENDO Registration. Reserve your space at this year’s meeting and book your hotel before…
Join us as we discuss the impact of blood pressure on your body. From eyes to heart to kidneys, blood pressure management is key to…
Unlock the Power to Transform Lives: Discover the keys to clinically meaningful weight loss thresholds and revolutionize your approach to tackling obesity complications! In our…
Type 2 diabetes diagnosed in childhood or early adulthood is termed early-onset type 2 diabetes. Cases of early-onset type 2 diabetes are increasing rapidly globally,…
Increasing numbers of doctors are leaving the specialty or switching to private practice, leaving millions without effective primary care. Paul Webster reports.
We have identified two subphenotypes within ARDS, one of which is categorised by more severe inflammation, shock, and metabolic acidosis and by worse clinical outcomes.…